Discovery and structure-activity relationships study of positive allosteric modulators of the M3 muscarinic acetylcholine receptor

  • Bioorg Med Chem. 2020 Jul 1;28(13):115531. doi: 10.1016/j.bmc.2020.115531.
Hiroaki Tanaka  1 Kenji Negoro  2 Takanori Koike  1 Issei Tsukamoto  1 Kazuhiro Yokoyama  1 Jun Maeda  1 Yusuke Inagaki  1 Yukinori Shimoshige  1 Katsutoshi Ino  1 Kenichiro Ishizu  1 Taisuke Takahashi  1
Affiliations
  • 1. Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.
  • 2. Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. Electronic address: [email protected].
Abstract

The M3 Muscarinic Acetylcholine Receptor (mAChR) is a member of the family of mAChRs, which are associated with a variety of physiological functions including the contraction of various smooth muscle tissues, stimulation of glandular secretion, and regulation of a range of cholinergic processes in the central nerve system. We report here the discovery and a comprehensive structure--activity relationships (SARs) study of novel positive allosteric modulators (PAMs) of the M3 mAChR through a high throughput screening (HTS) campaign. Compound 9 exhibited potent in vitro PAM activity towards the M3 mAChR and significant enhancement of muscle contraction in a concentration-dependent manner when applied to isolated smooth muscle strips of rat bladder. Compound 9 also showed excellent subtype selectivity over Other subtypes of mAChRs including M1, M2, and M4 mAChRs, and moderate selectivity over the M5 mAChR, indicating that compound 9 is an M3-preferring M3/M5 dual PAM. Moreover, compound 9 displayed acceptable pharmacokinetics profiles after oral dosing to rats. These results suggest that compound 9 may be a promising chemical probe for the M3 mAChR for further investigation of its pharmacological function both in vitro and in vivo.

Keywords
Allosteric enhancers; M(3) muscarinic acetylcholine receptor; Positive allosteric modulators.
Products